Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab
| Image |  |
|---|---|
| Description | scientific article published on 05 December 2018 |
| Author/s |
author: Johannes Breyer Simone Bertz Arndt Hartmann Maximilian Burger Wilko Weichert |
| Publication date | December 5, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |